Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma

European Journal of Surgical Oncology

Volumn 32, Issue 3, 2006, Pages 297-302

  Ridwelski, Karsten ^a,b   Fahlke, J ^a   Kuhn, R ^a   Hribaschek, A ^a   Kettner, E ^b   Greiner, C ^c   Florschuetz, A ^d   Manger, T ^d   Wilhelm, G ^e   Klein, H ^f   Hahnfeld, S ^g   Lippert, H ^a   Meyer, F ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b Municipal Hospital   (Germany)

^c Municipal Hospital   (Germany)

^d Municipal Hospital   (Germany)

^e District Hospital   (Germany)

^f Department of Medicine   (Germany)

^g NONE

Author keywords

Docetaxel; Gemcitabine; Metastases; Pancreatic carcinoma; Phase I II study

Indexed keywords

DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; MITOMYCIN; ONDANSETRON;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; EDEMA; FACE DEFORMITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; METASTASIS; MULTICENTER STUDY; NEUROTOXICITY; PANCREAS CARCINOMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RIBONUCLEOTIDE REDUCTASES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 33645051717     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.11.020     Document Type: Article

References (26)

1. H.A. Burris M.J. Moore J. Andersen MR Green ML Rothenberg MR Modiano et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403-2413
2. M.A. Friedman M.J. Cassidy J.F. Hannigan et al. A phase III study of adriamycin+5FU vs BCNU+adriamycin+ftorafur for patients with advanced pancreatic cancer Proc Am Assoc Cancer Res Am Soc Clin Oncol 22 1981 156
3. D. Kelsen C. Hudis D. Niedzwiecki J Dougherty E Casper J Botet et al. A phase III comparison trial of streptozotosin, mitomycin and 5-FU with cisplatin, cytosine arabinoside and caffeine in patients with advanced pancreatic carcinoma Cancer 68 1991 965-969
4. P. Rougier M. De Forni A. Adenis Phase II study of taxotere in pancreatic cancer Proc Am Soc Clin Oncol 13 1994 200-205
5. M.L. Rothenberg J.L. Abbruzzese M. Moore RK Portenoy JM Robertson HJ Wanebo A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma Cancer 67 1996 627-632
6. V. Heinemann Gemcitabine: Progress in the treatment of pancreatic cancer Oncology 60 2001 8-18
7. A.D. Jacobs Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations Cancer 95 Suppl 4 2002 923-927
8. H. Oettle D. Arnold C. Hempel H. Riess The role of gemcitabine alone and in combination in the treatment of pancreatic cancer Anticancer Drugs 11 10 2000 771-785
9. M. Moore Activity of gemcitabine in patients with advanced pancreatic cancer Cancer 78 1996 633-638
10. E.A.D. Poplin T. Corbett L. Flaherty Difluorodeoxycytidine (dFdC)-gemcitabine: A phase I study Invest New Drugs 10 1992 165-170
11. R. Simon Randomized clinical trials in oncology: Principles and obstacles Cancer 74 1994 2614
12. J. Glenn W.M. Steinberg S.H. Kurtzmann SM Steinberg WF Sindelar Evaluation of the utility of a radio immunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas J Clin Oncol 6 1988 462-468
13. H. Ishii S. Okada T. Sato H Wakasugi H Saisho J Furuse et al. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer Hepatogastroenterology 44 13 1997 279-283
14. B. Glimelius K. Hoffmann P.O. Sjödén G Jacobsson H Sellstrom LK Enander et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 1996 593-600
15. S. Cascinu G. Gasparini V. Catalano RR Silva G Pancera A Morabito et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD) Ann Oncol 10 1999 1377-1379
16. J.W. Clark D.P. Ryan M.H. Kulke M Grossbard Ch Fuchs S Grossman et al. Phase II-study of gemcitabin and docetaxel in patients with metastatic pancreatic cancer Proc Am Soc Clin Oncol 2000 1238 [abstr]
17. S. Kakolyris G. Stathopoulos N. Tsavaris N Androulakis Ch Kouroussis E Samantas et al. First line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced pancreatic cancer: A multicenter phase II study Proc Am Soc Clin Oncol 18 1999 960 [abstr]
18. A.D. Jacobs H. Otero V. Picozzi D.M. Aboulafia Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic cancer Cancer Invest 22 4 2004 505-514
19. C.H. Spiridonidis L.R. Laufman J. Jones VA Rhodes K Wallace S Nicol et al. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies J Clin Oncol 16 12 1998 3866-3873
20. N.A. Rizvi Docetaxel (taxotere) and gemcitabine in combination therapy Semin Oncol 26 3 Suppl 11 1999 19-22
21. D. Rischin M. Boyer J. Smith M Millward M Michael J Bishop et al. A phase I trial of docetaxel and gemcitabine in patients with advanced cancer Ann Oncol 11 4 2000 421-426
22. D.P. Ryan T.J. Lynch M.L. Grossbard MV Seiden CS Fuchs N Grenon et al. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors Cancer 88 1 2000 180-185
23. K. Ridwelski A. Lueck H. Lippert Phase I study of a treatment with gemcitabine and docetaxel weekly in advanced pancreatic cancer Proc 17th Int Cancer Congr (UICC) 330 1998 [abstr 1411]
24. K.N. Ganjoo M.S. Gordon A.B. Sandler RE Warner K Fife S Poirier et al. A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group Study Oncology 62 4 2002 299-304
25. G.P. Stathopoulos D. Mavroudis N. Tsavaris C Kouroussis G Aravantinos S Agelaki et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer Ann Oncol 12 1 2001 101-103
26. D.P. Ryan M.H. Kulke C.S. Fuchs ML Grossbard SR Grossman JA Morgan et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma Cancer 94 1 2002 97-103